JCXH 108
Alternative Names: JCXH-108Latest Information Update: 10 Oct 2024
Price :
$50 *
At a glance
- Originator Immorna
- Class Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 23 Sep 2024 Phase- I clinical trials in Respiratory syncytial virus infections (Prevention) in USA (IM) (NCT06564194)
- 27 Aug 2024 Pharmacodynamics data from a preclinical studies in Respiratory syncytial virus infections released by Immorna Biotherapeutics
- 22 Aug 2024 Immorna Biotherapeutics plans a phase I trial for Respiratory syncytial virus (Prevention) in August 2024 (IM) (NCT06564194)